Seaport Therapeutics Q2 2026: $427M Cash, Pipeline Progress, and $260M Upsized IPO
SPTX sits 38% above its 52-week low of $14.85.
Summary
Seaport Therapeutics posted Q2 2026 results with $427.3 million in cash, expected to fund operations into 2029. Enrollment in its pivotal depression trial remains on track, and the company plans to initiate two Phase 2 trials for its anxiety drug later this year.
Key Events · Earnings and Guidance · SPTX
-
Strong Cash Position
Cash, cash equivalents, and investments totaled $427.3 million as of June 30, 2026, following a $260.0 million upsized IPO in May 2026. Management expects this to fund operations into 2029, covering multiple clinical data readouts.
-
Q2 2026 Net Loss
Net loss was $62.6 million, up from $15.1 million in Q2 2025, primarily due to a one-time, non-cash stock-based compensation charge of $36.0 million related to the IPO. R&D expenses rose to $24.6 million as programs advanced.
-
GlyphAllo Depression Program On Track
Enrollment in the Phase 2b BUOY-1 trial for major depressive disorder is on track, with topline data expected in the first half of 2027. A Phase 1 driving simulation safety study is expected to report data in the second half of 2026.
-
GlyphAgo Anxiety Program Advancing
Following positive Phase 1 proof-of-concept results, Seaport plans to initiate a Phase 2a trial in generalized anxiety disorder (GAD) with sleep disturbance in 2H 2026, and a Phase 2b trial in GAD in 1H 2027.
Analysis · SPTX · Life Sciences
Seaport Therapeutics reported a second-quarter 2026 net loss of $62.6 million, largely reflecting a one-time, non-cash stock-based compensation charge tied to its IPO. The company ended the quarter with $427.3 million in cash and investments, a balance that management expects to fund operations into 2029 — effectively removing near-term financing risk. Its lead depression candidate, GlyphAllo, remains on track for pivotal data in the first half of 2027, with a driving-simulation safety study reading out later this year. Meanwhile, the anxiety program GlyphAgo is advancing into two Phase 2 trials starting later this year, following positive proof-of-concept data. These milestones, combined with the upsized $260 million IPO completed in May, position the company to reach multiple value-creating catalysts without needing to raise additional capital.
At the time of this filing, SPTX was trading at $20.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $14.85 to $22.98. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.